Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.47 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.47 |
| ▸ | TTR | P02766 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.46 |
| ▸ | BTK | Q06187 | 1/20 | 0.40 |
| ▸ | MALT1 | Q9UDY8 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13213549 | 1.00 | ESR1 (0.47) | ESR1ESR2TTREPHX2MTNR1A | |
| SCHEMBL17478347 | 0.86 | MALT1 (0.46) | EPHX2MTNR1ABTKMALT1KMT2A | |
| SCHEMBL17478346 | 0.86 | MALT1 (0.46) | EPHX2MTNR1ABTKMALT1KMT2A | |
| SCHEMBL17478422 | 0.86 | EPHX2 (0.45) | EPHX2MTNR1ABTKMALT1KMT2A | |
| SCHEMBL17478326 | 0.86 | EPHX2 (0.45) | EPHX2MTNR1ABTKMALT1KMT2A | |
| SCHEMBL17478454 | 0.86 | EPHX2 (0.45) | EPHX2MTNR1ABTKMALT1KMT2A | |
| SCHEMBL22472834 | 0.83 | EPHX2 (0.59) | EPHX2MTNR1AMALT1KMT2AL3MBTL1 | |
| SCHEMBL390212 | 0.82 | EPHX2 (0.51) | ESR2EPHX2BTKKMT2AL3MBTL1 | |
| SCHEMBL20722424 | 0.82 | ESR1 (0.52) | ESR1ESR2TTRMTNR1ALMNA | |
| SCHEMBL18983627 | 0.82 | ESR1 (0.52) | ESR1ESR2TTRMTNR1ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10280159-B2 | Fused (hetero)cyclic compounds as S1P modulators | AbbVie Deutschland GmbH & Co. KG (DE) | 2019-05-07 | — | — | US | disclosed |
| WO-2017109095-A1 | FUSED (HETERO)CYCLIC COMPOUNDS AS S1P MODULATORS | AbbVie Deutschland GmbH & Co. KG (DE) | 2017-06-29 | — | — | WO | disclosed |
| US-20170174672-A1 | FUSED (HETERO)CYCLIC COMPOUNDS AS S1P MODULATORS | AbbVie Deutschland GmbH & Co. KG (DE) | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10280159-B2 | Fused (hetero)cyclic compounds as S1P modulators | S1PR1, S1PR2, S1PR3 | ESR1 1538/4885ESR2 422/4885TTR 4346/4885 |
| US-20170174672-A1 | FUSED (HETERO)CYCLIC COMPOUNDS AS S1P MODULATORS | S1PR1, S1PR2, S1PR3 | ESR1 1538/4885ESR2 422/4885TTR 4346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.